Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts

J. Ring*, M. Worm, A. Wollenberg, J. P. Thyssen, T. Jakob, L. Klimek, C. Bangert, S. Barbarot, T. Bieber, M. S. deBruin-Weller, P. V. Chernyshov, S. Christen-Zaech, M. Cork, U. Darsow, C. Flohr, R. Foelster-Holst, C. Gelmetti, U. Gieler, J. Gutermuth, A. HeratizadehD. J. Hijnen, L. B. vonKobyletzki, B. Kunz, C. Paul, L. De Raeve, J. Seneschal, D. Simon, P. I. Spuls, J. F. Stalder, A. Svensson, Z. Szalai, A. Taieb, A. Torrelo, M. Trzeciak, C. Vestergaard, T. Werfel, S. Weidinger, M. Deleuran

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

27 Citations (Scopus)
Original languageEnglish
Pages (from-to)e362-e365
Number of pages4
JournalJournal of the European Academy of Dermatology and Venereology
Issue number6
Early online dateApr 2021
Publication statusPublished - Jun 2021

Cite this